The index

Synthetic peptide derived from a stomach protein. Used to speed up tendon, ligament, and gut healing.

A fragment of Thymosin Beta-4. Drives cell migration and tissue repair, used for chronic soft-tissue stuff.

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

Tanning peptide that darkens your skin by driving melanin production. An alpha-MSH analog with a cleaner side effect profile than MT-2.

Supports collagen, wound healing, and hair follicles. A copper-binding tripeptide, used topical or sub-q.

Bumps your natural growth-hormone pulses without hitting cortisol or prolactin. A selective GH secretagogue.

Pairs with Ipamorelin to amplify your natural growth-hormone pulses. A GHRH analog whose 'no-DAC' version stays short-acting on purpose.

Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.

The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.

Tans your skin harder than MT-1 and also bumps libido, but brings rougher side effects. A less selective alpha-MSH analog.

Oral ghrelin mimetic. Bumps GH and IGF-1 without injections. Strong appetite stimulation is the trade-off.

Boosts libido and sexual desire. A melanocortin agonist, FDA-approved as Vyleesi for female sexual dysfunction and used off-label for libido in both sexes.

Used to shrink deep belly fat. A GHRH analog that's FDA-approved for HIV-associated lipodystrophy and used off-label for visceral fat reduction.

The gentle, older option for restoring your body's natural growth hormone. A GHRH analog, the older sibling to Tesamorelin and CJC, with a gentler profile.

Studied as an anti-aging and sleep-cycle peptide. A tetrapeptide derived from epithalamin, looked at for telomerase activation and circadian / pineal support, with limited human data.

A fat-loss peptide. It's a modified fragment of HGH (residues 176-191) that targets fat metabolism without the full GH side effect profile.

An experimental fat-loss compound. An NNMT inhibitor that targets the enzyme driving metabolic stagnation in obesity, with animal and in-vitro data only and no published human results.

Calms inflammation in the gut and skin. A tripeptide fragment of alpha-MSH used for gut conditions and skin inflammation.

Russian-origin synthetic peptide. Anxiolytic and cognitive support without the sedation profile of benzos.

Aimed at metabolism and exercise performance. A mitochondrial-derived peptide that targets metabolic flexibility, insulin sensitivity, and exercise response.

Recombinant human growth hormone, the protein itself, not a peptide that nudges your body to make more. Highest legal-risk compound in this catalog.

An appetite-control shot for weight loss. A long-acting amylin agonist that works on a different pathway than the GLP-1 drugs, often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus.

A weight-loss drug built for a stronger fat-burn signal than GLP-1-only options. A dual agonist (GLP-1 + glucagon) from Boehringer Ingelheim / Zealand Pharma, where glucagon activation boosts metabolic rate.

Used to drive muscle growth. A long-acting form of insulin-like growth factor 1, with limited human safety data and a real side effect profile, handle with discipline.

The hardest-hitting growth-hormone booster in this class. The most potent GH secretagogue, it gives a stronger pulse than Ipamorelin but with cortisol and prolactin bumps, so short cycles only.

Delta Sleep-Inducing Peptide. A brain-origin peptide aimed at sleep architecture. Limited human data, mixed user reports.

The fat-loss tail of the HGH molecule, isolated and used alone. Goal: trigger lipolysis without GH's water retention or insulin impact.

Aimed at brain aging and your body clock. A Russian-origin tripeptide (Glu-Asp-Arg) with limited human data, so treat it as experimental.

Immune-system peptide. Approved in many countries for hepatitis B/C and as adjunct to chemotherapy. Used here for chronic immune issues and post-illness recovery.

For alertness and focus. A Russian-origin nootropic peptide on the alert/focus end of the spectrum that pairs with Selank for a balanced cognitive stack.

Older growth-hormone boosters and the predecessors to Ipamorelin. These GH secretagogues split two ways: GHRP-2 is the cleaner, GHRP-6 brings stronger appetite stimulation.

Kick-starts your body's own testosterone production at the very top. It sits upstream of the entire HPG axis, triggering the natural cascade of GnRH → LH → testosterone, a different lever than the melanocortin libido peptides.

The 'bonding hormone' you make naturally. Synthetic oxytocin is FDA-approved for labor; off-label use covers social, anxiety, and intimacy contexts.

A weight-loss shot already approved in China. Innovent Biologics' GLP-1 + glucagon dual agonist out of China, with strong Phase 3 data and a 2025 China approval for obesity.

Boosts your cells' energy production at the source. A mitochondria-targeting peptide that concentrates in the inner mitochondrial membrane to support ATP production, FDA-approved in 2025 as FORZINITY for Barth syndrome, the first mitochondria-targeted drug, with all other uses off-label.

A germ-fighter your immune system already makes on its own. It's a cathelicidin-derived antimicrobial peptide used for chronic infections and biofilm-associated issues.

A compound aimed at unlocking muscle growth by releasing the body's natural brake on it. A myostatin antagonist that binds and neutralizes myostatin, the negative regulator of muscle growth. Theoretical muscle-growth signal, limited human data.

A compound studied for protecting the brain and keeping cells alive and insulin-sensitive as you age. A mitochondrial-derived peptide encoded inside mitochondrial DNA, studied for neuroprotection, insulin sensitivity, and cellular survival.

A muscle-growth compound that works more on the local muscle than the whole body. A truncated IGF-1 variant (missing the first 3 amino acids) that acts more locally than IGF-1 LR3, with shorter duration and (in theory) less systemic exposure.

A compound studied for calming nerve pain and inflammation without raising red blood cells. An EPO-derived peptide that targets the innate-repair receptor without the red-blood-cell side of erythropoietin, studied for neuropathic pain, sarcoidosis, and diabetic complications.

A brain compound aimed at building new connections between neurons. An angiotensin IV analog with strong synaptogenic effect in animal models, often-cited as 'BDNF on steroids.' Very limited human data.

A bone-building drug. A parathyroid-hormone fragment (PTH 1-34), FDA-approved as Forteo for severe osteoporosis. Anabolic for bone, the opposite of bisphosphonates.

A family of short (2-4 amino acid) peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology. Tissue-specific organ-support peptides. Limited Western clinical data.

A muscle-building drug that blocks the body's brake on muscle, shelved over safety. A soluble activin receptor IIB fused to Fc that traps myostatin and related TGF-β ligands. Acceleron developed it; Phase 2 dosing was halted in 2011 over vascular safety signals (program permanently discontinued 2013).

A peptide promoted for hair growth. A copper-binding tripeptide cousin to GHK-Cu, promoted specifically for hair-follicle support. Limited human data, most evidence is in vitro and topical formulation.

A compound aimed at reducing scar-tissue buildup (fibrosis). A single-chain peptide derivative of relaxin, designed to retain anti-fibrotic activity without the cardiovascular side profile of full relaxin. Pre-clinical / early human research.

A brain-recovery drug used abroad for stroke, head injury, and Alzheimer's. A porcine brain-derived peptide complex used clinically in 50+ countries (Russia, China, Mexico, EU) for stroke recovery, TBI, and Alzheimer's. It's a mixture of low-molecular-weight peptides, not a single compound.

A compound studied to protect the brain cells lost in Parkinson's. An 11-amino-acid peptide from the proGDNF domain (the prodomain of glial cell line-derived neurotrophic factor, GDNF), also called Dopamine Neuron Stimulating Peptide-11. Pre-clinical neuroprotection for dopaminergic neurons in Parkinson's models.

Studied for memory and learning in animal models. It's an FG-loop peptide modeled on the FG-loop region of NCAM (neural cell adhesion molecule).

FOXO4 dominant-negative interfering peptide. Selectively triggers apoptosis in senescent cells by disrupting FOXO4-p53 interaction. Animal-model senolytic with strong age-reversal data in mice.

Splice variant of IGF-1 produced by muscle in response to mechanical loading and damage. Triggers satellite cell activation. Short half-life, superseded for most use cases by PEG-MGF.

Synthetic ciliary neurotrophic factor (CNTF)-mimetic peptide. Targets neurogenesis. Pre-clinical / early research compound.

Synthetic peptide derived from spadin. TREK-1 channel inhibitor with rapid antidepressant effects in animal models. Pre-clinical.

PEGylated Mechano Growth Factor. Polyethylene glycol attachment extends MGF's half-life from minutes to hours, allowing systemic muscle effects rather than purely local.

Membranolytic peptide that selectively kills cancer cells expressing HDM-2 (oncoprotein) on the membrane surface. Pre-clinical anti-cancer research compound.

Topical Botox-mimic peptide. Interferes with SNAP-25 to reduce neuromuscular signaling at the skin surface, softening expression lines.

Endogenous 28-amino-acid neuropeptide. Modulates immune function and inflammation. Used in CIRS (chronic inflammatory response syndrome) protocols and biotoxin exposure recovery, popularized by Dr. Ritchie Shoemaker.

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.

A drug that shuts down the body's overproduction of growth hormone, used for conditions like acromegaly. A synthetic somatostatin analog, FDA-approved in 1988 for acromegaly, carcinoid syndrome, and VIPomas; it suppresses GH and IGF-1, the mechanistic opposite of Tesamorelin.

A weight-loss drug for rare genetic forms of obesity. An MC4R agonist, FDA-approved in 2020 for obesity due to POMC, PCSK1, or LEPR deficiency and in 2022 for Bardet-Biedl syndrome; it's the educational anchor for melanocortin-pathway weight regulation.

A mealtime injection that curbs appetite and steadies blood sugar in diabetics. A synthetic analog of amylin (the satiety hormone co-secreted with insulin), FDA-approved in 2005 as a mealtime adjunct in type 1 and type 2 diabetes, and the clinical predecessor to Cagrilintide.

A gut drug that helps people with short bowel syndrome absorb more nutrients. A recombinant GLP-2 analog, FDA-approved in 2012 for short bowel syndrome with intestinal failure; it hits a different receptor and indication than the GLP-1 weight-loss drugs.

Zealand Pharma's long-acting amylin analog (partnered with Roche). Phase 2 complete, Phase 3 planned for H2 2026. A competing once-weekly amylin analog, not a Novo or Cagrilintide successor.

Altimmune's GLP-1 + glucagon dual agonist. Phase 2 data shows weight loss alongside meaningful liver-fat reduction (NASH/MASH applications). Direct competitor to Retatrutide and Survodutide.

Novo Nordisk's single-molecule GLP-1 + amylin co-agonist. Phase 1/2 in oral and subcutaneous formulations. The pharmacological consolidation of the Semaglutide + Cagrilintide concept into one peptide.

Used to rebuild a weakened immune system, mainly in older or post-illness patients. A polypeptide complex extracted from calf thymus and distinct from Thymosin Alpha-1, used in Russian and Eastern European clinical practice for immune restoration in elderly patients and post-illness recovery.

Used clinically to boost fertility and restart the body's own testosterone production after a suppressive cycle. It's a glycoprotein hormone that works by mimicking LH at the testicular Leydig cell.